Empagliflozin
Empagliflozin is a pharmaceutical drug with 173 clinical trials. Currently 32 active trials ongoing. Historical success rate of 93.6%.
Success Metrics
Based on 103 completed trials
Phase Distribution
Phase Distribution
26
Early Stage
34
Mid Stage
79
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
85.8%
103 of 120 finished
14.2%
17 ended early
32
trials recruiting
173
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
Clinical Trials (173)
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 Diabetes
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Comparative Effectiveness of Empagliflozin in the US
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims Data
Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims Data
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Efficacy and Safety of Empagliflozin in GSD-Ib Patients
SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome
Vascular Effects of SGLT2i in Non-diabetic CKD
EMPagliflozin After Aortic Valve Replacement
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 173